Review Article

You have full text access to this OnlineOpen article

Preoperative chemotherapy treatment of breast cancer—A review

  1. Aman U. Buzdar MD†,*

Article first published online: 16 OCT 2007

DOI: 10.1002/cncr.23083

Issue

Cancer

Cancer

Volume 110, Issue 11, pages 2394–2407, 1 December 2007

Additional Information

How to Cite

Buzdar, A. U. (2007), Preoperative chemotherapy treatment of breast cancer—A review. Cancer, 110: 2394–2407. doi: 10.1002/cncr.23083

Author Information

  1. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794–4385.

*Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard-1354, Houston, TX 77030

Publication History

  1. Issue published online: 19 NOV 2007
  2. Article first published online: 16 OCT 2007
  3. Manuscript Accepted: 12 JUN 2007
  4. Manuscript Revised: 7 JUN 2007
  5. Manuscript Received: 24 APR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (147K)

REFERENCES

  • 1
    Kaufmann M,Hortobagyi GN,Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006; 24: 1940–1949.
  • 2
    Cleator S,Parton M,Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer. 2002; 9: 183–195.
  • 3
    Charfare H,Limongelli S,Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005; 92: 14–23.
    Direct Link:
  • 4
    Feldman LD,Hortobagyi GN,Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986; 46: 2578–2581.
  • 5
    Kuerer HM,Newman LA,Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460–469.
  • 6
    Bear HD,Anderson S,Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24: 2019–2027.
  • 7
    Sataloff DM,Mason BA,Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995; 180: 297–306.
  • 8
    Wolmark N,Wang J,Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96–102.
  • 9
    Chevallier B,Roche H,Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993; 16: 223–228.
  • 10
    Sahin A. Surgical margin evaluation in patients treated with breast-conserving therapy. In: SingletarySE,RobbG,HortobagyiRN, eds. Advanced Therapy of Breast Disease,2nd ed. Hamilton, Ontario, Canada: BC Decker Inc.; 2004: 341–348.
  • 11
    Schnitt SJ,Connolly JL. Processing and evaluation of breast excision specimens. A clinically oriented approach. Am J Clin Pathol. 1992; 98: 125–137.
  • 12
    Buzdar AU,Singletary SE,Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17: 3412–3417.
  • 13
    Makris A,Hisenbeck SG,Yee D, et al. A prospective randomized multicenter gene expression study of docetaxel vs doxorubicin/cyclophosphamide preoperative trial in primary breast cancers. J Clin Oncol. 2005; 23(pt I of II): 16S. Abstract 544.
  • 14
    Chang J,Hilsenbeck S,Yee D, et al. Gene expression profiles as predictors of response to neoadjuvant Taxotere and Adriamycin/cytoxan: a prospective randomized multicenter trial in breast cancer. [Abstract.] Breast Cancer Res Treat. 2005; 94( suppl 1): 304.
  • 15
    Formenti S,Spicer D,Skinner K. Paclitaxel alone and in combination with radiation therapy as neoadjuvant approach to locally advanced breast cancer (LABC): clinical and pathological response. Proc Am Soc Clin Oncol. 2001; 20: 39b. Abstract 1902.
  • 16
    Formenti SC,Volm M,Skinner KA, et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003; 21: 864–870.
  • 17
    Overmoyer B,Silverman P,Leeming R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. [Abstract.] Breast Cancer Res Treat. 2004; 88: 2088.
  • 18
    Lyons J,Silverman P,Remick S, et al. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol. 2006; 24(pt I): 18S. Abstract 3049.
  • 19
    Chua S,Smith IE,A'Hern RP, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol. 2005; 16: 1435–1441.
  • 20
    Dieras V,Fumoleau P,Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004; 22: 4958–4965.
  • 21
    Evans TR,Yellowlees A,Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol. 2005; 23: 2988–2995.
  • 22
    Fenton M,Ries L,Strenger RS, et al. Frequent pathologic complete responses seen with neoadjuvant q4week carboplatin and weekly paclitaxel ± weekly trastuzumab in resectable and locally advanced breast cancer: a Brown University Oncology Group (BrUOG) study. [Abstract.] Breast Cancer Res Treat. 2005; 94( suppl 1): 5054.
  • 23
    Reitsamer R,Peintinger F,Prokop E, et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs. 2005; 16: 867–870.
  • 24
    Romieu G,Tubiana-Hulin M,Fumoleau P. A multicenter randomized phase II study of 4 or 6 cycles of Adriamycin/taxol (paclitaxel) AT as neoadjuvant treatment of breast cancer (BC). Ann Oncol. 2002; 13( suppl 5): 33–34. Abstract 118.
  • 25
    Steger GG,Kubista E,Hausmaninger H, et al. Six versus 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2004; 22: 14S. Abstract 553.
  • 26
    Tong F,Yang D,Zhou B, et al. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer—comparative study of treatment with 2 and 4 cycles]. Gan To Kagaku Ryoho. 2004; 31: 205–208.
  • 27
    Euler U,Dresel V,Bhner M, et al. Dose and time intensified epirubicin/cyclophosphamide (EC) as preoperative treatment in locally advanced breast cancer. [Abstract.] Breast Cancer Res Treat. 2002; 76: 154.
  • 28
    Scholl SM,Fourquet A,Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994; 30A: 645–652.
  • 29
    Powles TJ,Hickish TF,Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995; 13: 547–552.
  • 30
    Smith IE,A'Hern RP,Coombes GA, et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004; 15: 751–758.
  • 31
    Pierga J-Y,Girre V,Beuzeboc P. Randomized trial of neoadjuvant chemotherapy in operable breast cancer comparing Adriamycin-cyclophosphamide (CPM)-5FU (ACF) versus thiotepa-CPM-5FU (TCF). Ann Oncol. 2000; 11( suppl 4): 24. Abstract 97PD.
  • 32
    Yang D,Tong F,Cao Y, et al. [Evaluation of 2 different regimens as neoadjuvant chemotherapy for breast cancer]. Zhonghua Zhong Liu Za Zhi. 2002; 24: 303–305.
  • 33
    Vallejo CT,Lacava JA,Perez JE, et al. Prognostic factors in locally advanced breast carcinoma (LABC): randomized phase-II trial of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) vs. cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Proc Am Soc Clin Oncol. 2003; 22: 73. Abstract 293.
  • 34
    Therasse P,Mauriac L,Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003; 21: 843–850.
  • 35
    Pelissier P,Delaloge,Mathieu M-C, et al. Intensified anthracycline doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial. Proc Am Soc Clin Oncol. 2002; 21: 64a. Abstract 254.
  • 36
    Dhingra K,Esparza-Guerra L,Valero V, et al. A phase III randomized trial of dose-intensive, neoadjuvant 5FU, doxorubicin, cyclophosphamide (FAC) with G-CSF (filgrastim) in locally advanced breast cancer (LABC)-efficacy and safety data. Proc Am Soc Clin Oncol. 1999: 18; 74a. Abstract 278.
  • 37
    Boddie AW,Warso M,Briele H, et al. Multimodal-therapy breast salvage in the urban poor with locally advanced cancer. Arch Surg. 1996; 131: 424–429.
  • 38
    Moliterni A,Tarenzi E,Capri G. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol. 1997; 24( Suppl 17): 10–14.
  • 39
    Pierga JY,Laine-Bidron C,Beuzeboc P, et al. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 1997; 76: 537–540.
  • 40
    Adkins D,Brown R,Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol. 1999; 17: 2006–2014.
  • 41
    Chang H,Slamon D,Prati R, et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity. J Clin Oncol. 2006; 24: 18S. Abstract 10515.
  • 42
    Norton L,Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986; 70: 163–169.
  • 43
    Ocana A,Hortobagyi GN,Esteva FJ. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer. 2006; 6: 495–504.
  • 44
    Bear HD,Anderson S,Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 4165–4174.
  • 45
    von Minckwitz G,Raab G,Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the Gepar-DUO study of the German Breast Group. J Clin Oncol. 2005; 23: 2676–2685.
  • 46
    Heys SD,Hutcheon AW,Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002; 3( suppl 2): S69–S74.
  • 47
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 1456–1466.
  • 48
    Toi M,Bando H,Horiguchi S, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer. 2004; 90: 2338–2343.
  • 49
    Limentani S,Brufsky A,Rubin P, et al. A phase II randomized study to compare the neoadjuvant administration of docetaxel and vinorelbine or docetaxel followed by Adriamycin and cytoxan with all chemotherapy administered in a dose dense fashion to women with stage II and stage III breast cancer. [Abstract.] Breast Cancer Res Treat. 2005; 94( suppl 1): 5055.
  • 50
    Miller KD,McCaskill-Stevens W,Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999; 17: 3033–3037.
  • 51
    Untch M,Konecny G,Ditsch N. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol. 2002; 21: 34a. Abstract 133.
  • 52
    Gianni L,Baselga J,Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005; 11: 8715–8721.
  • 53
    von Minckwitz G,Blohmer JU,Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the Gepar-TRIO pilot study. Ann Oncol. 2005; 16: 56–63.
  • 54
    von Minckwitz G,Blohmer J,Vogel P, et al. Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TAC×2-the Gepar-TRIO Study. J Clin Oncol. 2006; 24: 18S. Abstract 576.
  • 55
    Thomas E,Holmes FA,Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004; 22: 2294–2302.
  • 56
    Green MC,Buzdar AU,Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 5983–5992.
  • 57
    Buzdar AU,Ibrahim NK,Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–3685.
  • 58
    Buzdar AU,Valero V,Ibrahim N, et al. Neoadjuvant therapy with paclitaxel followed by FEC chemotherapy and concurrent trastuzumab in HER2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228–233.
  • 59
    Mauriac L,Durand M,Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991; 2: 347–354.
  • 60
    Mauriac L,MacGrogan G,Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10: 47–52.
  • 61
    Shenkier T,O'Reilly S,Gelmon K. A phase II trial of 2 different sequences of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in patients with locally advanced breast cancer. Expression of markers over time. Breast Cancer Res Treat. 2003; 82( suppl 1): S57. Abstract 246.
  • 62
    Rajan R,Poniecka A,Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. 2004; 100: 1365–1373.
    Direct Link:
  • 63
    Symmans W,Peintinger F,Hatzis C, et al. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2006; 24: 18S. Abstract 536.
  • 64
    Bollag DM,McQueney PA,Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995; 55: 2325–2333.
  • 65
    Bode CJ,Gupta MLJr,Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002; 41: 3870–3874.
  • 66
    Hofle G,Bedorf N, inventors. Epothilone: deren herstellungsverfahren sowie sie enthaltende mittel. German Patent No. DE4138042. 1993.
  • 67
    Hofle G,Bedorf N,Steinmetz H, et al. Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and confirmation in solution. Angew Chem Int Ed Engl. 1996; 35: 1567–1569.
    Direct Link:
  • 68
    Altmann KH. Epothilone B and its analogs—a new family of anticancer agents. Mini Rev Med Chem. 2003; 3: 149–158.
  • 69
    Low JA,Wedam SB,Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005; 23: 2726–2734.
  • 70
    Galsky MD,Small EJ,Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005; 23: 1439–1446.
  • 71
    Vansteenkiste JF,Breton J-L,Sandler A, et al. A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. J Clin Oncol. 2003; 22: 626. Abstract 2519.
  • 72
    Fojo AT,Menefee ME,Poruchynsky M, et al. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol. 2005; 23: 388S. Abstract 4541.
  • 73
    O'Connor O,Straus D,Moskowitz C, et al. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease. J Clin Oncol. 2005; 23: 577s. Abstract 6569.
  • 74
    Whitehead RP,McCoy S,Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC 710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs. 2006; 24: 515–520.
  • 75
    Thomas E,Perez EA,Mukhopadhyay P, et al. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol. 2006; 24: 18S. Abstract 660.
  • 76
    Hsin KW,Boyer M,Ducreux M, et al. Efficacy of patupilone in advanced local or metastatic gastric cancer: a phase IIa trial. J Clin Oncol. 2006; 24: 18S. Abstract 4069.
  • 77
    Buzdar A,Silverman P,Kaufman PA, et al. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. [Abstract.] Breast Cancer Res Treat. 2005; 94: 1087.
  • 78
    Yee L,Lynch T,Villalona-Calero M, et al. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol. 2005; 23: 16S. Abstract 7127.
  • 79
    Wartmann M,Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002; 2: 123–148.
  • 80
    Rothermel J,Wartmann M,Chen T, et al. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol. 2003; 30: 51–55.
  • 81
    Jordan MA,Miller H,Ray A, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res. 2006; 47. Abstract LB-280.
  • 82
    Zhuang SH,Agrawal M,Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 2005; 103: 1932–1938.
    Direct Link:
  • 83
    Baselga J,Gianni L,Llombart A, et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat. 2005; 94: S31. Abstract 305.
  • 84
    Lee H,Xu L,Wu S, et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. J Clin Oncol (ASCO Annual Meeting Proc). 2006; 24; 18S. Abstract 3011.
  • 85
    Roche H,Perez E,Llombart Cussac A, et al. Ixabepilone, an epothilone analog, is effective in ER-, PR-, HER-negative (triple negative) patients: data from neoadjuvant and metastatic breast cancer trials. Ann Oncol. 2006; 17( suppl 9): ix97. Abstract 256-P.
  • 86
    Chang JC,Wooten EC,Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362: 362–369.
  • 87
    Faneyte IF,Schrama JG,Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003; 88: 406–412.
  • 88
    Geisler S,Borresen-Dale AL,Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res. 2003; 9: 5582–5588.
View Full Article (HTML) Get PDF (147K)